FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	$D \subset$	205/10
vasiiiigioii,	D.C.	20349

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average b	urden									
hours per response.	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

																				,	
Name and Address of Reporting Person* Venker Eric						2. Issuer Name and Ticker or Trading Symbol Roivant Sciences Ltd. [ROIV]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Venter Life																Directo	r 10% Ow (give title Other (s				
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year)) X	below)	(Aive une		below)	рсспу	
(Last) (First) (Middle) C/O ROIVANT SCIENCES LTD.					06/	06/07/2023 President & COO															
7TH FLOOR, 50 BROADWAY					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)											olicable				
					-	X Form filed by One Reporting Person															
(Street) LONDON X0 SW1H 0DB				DВ		Form filed by More than One Reporting Person															
(City) (State) (Zip)				Rı	Rule 10b5-1(c) Transaction Indication																
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
		Tal	ble I - No	n-Deri	vative	e Se	ecur	ities Ac	cqu	ıired, I	Dis	posed o	of, or	Ben	eficially	Owned					
Da			Date	ansaction enth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		;	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			i (A) or : 3, 4 and 5) or 5. Amour 4 and 5) Securitie Beneficia Owned F		Form (D) o	n: Direct r Indirect	7. Nature of Indirect Beneficial Ownership		
									,	Code	v	Amount		(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)	
Common Shares				06/07	7/2023					M		201		A	\$3.85	660	660,298		D		
Common Shares				06/07	7/2023					S		201		D	\$9.85(1	660	660,097		D		
Common Shares 06				06/09	9/2023	2023			M		299,384		A	\$3.85	959,481			D			
Common Shares 06/09/2					9/2023	2023 s 299,384 D \$9.91 ⁽¹⁾ 660,097				,097		D									
			Table II -									osed of converti				Owned					
1. Title of Derivative Security (Instr. 3)	Conversion Date or Exercise (Month/Day/Year) if		3A. Deeme Execution if any (Month/Day	d Date,	4. Transac Code (Ir 8)	tion	5. Number of Derivative		6. Ex	Date Exe piration onth/Day	rcis Date	able and 7. Title and A of Securities		Amount s Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)		
					Code	v	(A)	(D)		Date Exercisable		expiration Date	Title	i	Amount or Number of Shares		(Instr. 4)	1011(3)			
Stock Option (Right to Buy)	\$3.85	06/07/2023			М			201		(2)	0	4/19/2032	Comn Shar		201	\$0	15,622,5	568	D		
Stock Option (Right to	\$3.85	06/09/2023			M			299,384	(2) 04/19/2032 Common Shares 299		299,384	\$0	15,323,184		D						

Explanation of Responses:

- 1. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.
- 2. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker

06/09/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.